Health
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
- Published
- (1 h ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 17-word snippet. The full article is at the source.
More from STAT News and around the same time
Are you pursuing MRT as a treatment for infertility?Are you pursuing MRT as a treatment for infertility? STAT wants to hear from youOpinion: Cancer patients are often pressured to end a pregnancy early. They shouldn’t beWomen can be safely treated for many cancers during pregnancy, a maternal fetal medicine specialist writes.Opinion: The economics of the U.S. health care system are broken“The economics of the U.S. health care system are broken,” writes Paul Markovich, president and CEO of Ascendiun.Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misledPioneering IVF technique to reduce the risk of children inheriting mitochondrial diseases is being marketed as a fertility procedure for older women, despite little evidence it works.STAT+: What are the health stakes of the midterms? Policymakers, lobbyists, and experts weigh inNo matter what happens on Election Day, the midterms will have sweeping implications for American health care. More than two dozen experts on what could come next.STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
